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The HIV pandemic continues to evolve in a spatially and socially dynamic manner. After peaking in 
1997, the average global incidence of HIV infections has dropped and stabilized to a certain degree 
(see figure). Nevertheless, national epidemics continue to grow in many parts of the world. For 
example, from 2001 to 2011 the rate of new HIV infections rose in Eastern Europe and Central Asia, 
and there was a concomitant shift in the primary route of infection in these regions from intravenous 
drug use to sexual transmission. Ongoing outbreaks of HIV are also occurring in the Middle East and 
North Africa (UNAIDS, 2012). Reliable methods for quantifying HIV incidence are needed to monitor 
the dynamic leading edge of the global pandemic. This, in turn, will facilitate the optimal allocation of 
key resources, such as prevention interventions and antiretroviral treatments, to populations at 
greatest risk. 
Simply put, 'incidence' is the rate at which new cases of a disease occur in a population over a given 
time period. Though this valuable measure of risk sounds straightforward enough, its assessment is 
far from trivial, particularly in the case of HIV. In one approach for estimating incidence, a large HIV-
uninfected cohort is monitored over a long period of time for HIV seroconversion, requiring large 
investments of time and money. However, the individuals at highest risk of infection are often the 
most difficult to follow. An alternative approach for estimating incidence measures the prevalence of 
acute HIV infections at essentially a single time point in a random cross-section of a focal population. 
The 'acute' period of HIV infection typically occurs 2-4 weeks after infection, and infections are 
classified as 'recent' for 5-6 months following infection. Though cross-sectional studies can be 
carried out more widely and rapidly than cohort studies, their limitations include brevity of the acute 
stage of HIV infection and the imprecision of any one serological method for detecting acute HIV 
infection. 
Recently, Oliver Laeyendecker of the National Institute of Allergy and Infectious Diseases and Dr. 
Susan Eshleman of the Johns Hopkins University School of Medicine led a collaborative effort to 
develop a promising new algorithm for accurately detecting recent HIV infections in cross-sectional 
studies. A number of other scientists at different institutes contributed to this research, which is 
described in two papers jointly published in the Journal of Infectious Diseases, including Drs. 
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Deborah Donnell, James Hughes and Jing Wang of the Vaccine and Infectious Disease Division at 
the Fred Hutchinson Cancer Research Center. 
The most widely used serological assay for detecting recent HIV infection is the BED
TM
 capture 
enzyme immunoassay (BED-CEIA). This assay measures the ratio of anti-HIV IgG to total IgG and 
estimates recent infection based on assumptions regarding a monotonic increase in this ratio 
following HIV infection. However, it is now known that the BED-CEIA frequently misclassifies 
individuals with long-standing HIV infection as being recently infected. Laeyendecker et al. describe 
a hierarchical, multi-assay algorithm (MAA) for identifying recent HIV infections that builds upon the 
BED-CEIA assay. In the MAA, two serological tests help cast a broad net for recent infections: the 
BED-CEIA, which tests the proportion of antibodies that are HIV specific, and an assay that 
measures the avidity, or binding strength, of HIV antibodies to certain HIV antigens. These assays 
are combined with measurements of HIV viral loads and CD4 cell counts, which help to exclude 
false positives. By re-analyzing stored plasma and serum from HIV infected individuals who 
participated in three cohort studies in the United States, Laeyendecker et al. found that the MAA is 
as sensitive as the BED-CEIA for detecting recent HIV infection. However, unlike the BED-CEIA, 
which can cause false-recent misclassification for up to several years after infection, the probability 
of appearing recently infected on the basis of the MAA converges to zero within one year. 
In the companion paper, Eshleman et al. validated the performance of the MAA in detecting recent 
HIV infection using data and samples from the HIV Prevention Trials Network (HPTN) 064 Study – a 
cohort study enrolling 2,099 women at high risk for HIV acquisition in the United States. This allowed 
for a direct comparison of HIV incidence observed longitudinally to that estimated cross-sectionally. 
Once again, the researchers found that the MAA did not suffer from a propensity to overestimate 
recent infections, which characterized other serological measures applied to samples from the HPTN 
064 cohort. Moreover, HIV incidence estimated on the basis of a cross-sectional application of the 
MAA to these data closely matched the direct measurement of incidence on the basis of longitudinal 
seroconversion, although the number of seroconverters in this cohort was rather small. 
While AIDS-related illnesses are still among the leading causes of death worldwide, there are 
reasons to be optimistic about many trends in the HIV pandemic. According to the 2012 UNAIDS 
World AIDS Day Report, between 2001 and 2011 the rate of new HIV infections dropped by more 
than 50% in the adult populations of 25 countries. Fortunately, the work by Laeyendecker et al.and 
Eshleman et al. now equips the epidemiologist’s toolkit with a new monitoring instrument that will 
likely contribute to furthering these trends in the years to come. 
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World Health Organization 
Global annual incidence of new HIV infections (blue) and 
occurrence of AIDS-related deaths (red). The global 
peak in new HIV infections occurred in 1997, with the 
peak in AIDS-related deaths following eight years later. 
 
